文献速递垂体与肾上腺疾病性腺与生殖内分泌

促生长治疗对经典21-羟化酶缺陷症青春期、生长及最终身高影响

Impact of Growth-promoting Therapies on Puberty, Growth, and Final Height in Classical 21-hydroxylase Deficiency.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本研究为多中心回顾性纵向分析,纳入284例基因确诊的经典21-羟化酶缺陷症患者(46,XX 160例,46,XY 124例),评估青春期时机、持续时间、身高增长及最终身高,并分析促生长治疗(GnRH类似物、芳香化酶抑制剂、醋酸环丙孕酮)的效果。结果显示患者最终身高受损,青春期提前、节奏慢、持续时间长,尤其女孩;促生长治疗在男孩改善最终身高与遗传靶身高差值,在女孩则恶化。

要点

  • 经典21-OHD患者最终身高低于遗传靶身高,青春期提前、节奏慢、持续时间长。
  • 促生长治疗使男孩最终身高与遗传靶身高差值从-6.7 cm改善至-2.3 cm。
  • 促生长治疗使女孩最终身高与遗传靶身高差值从-3.7 cm恶化至-6.6 cm。

核心结论

  • 经典21-OHD患者虽早期诊断,最终身高仍受损。
  • 青春期表现为提前、节奏慢、持续时间长,尤其女孩。
  • 促生长治疗在女孩中促进身高效果较差,管理需个体化。

研究设计与样本

  • 多中心、回顾性、纵向分析,纳入284例基因确诊的经典21-OHD患者(46,XX 160例;46,XY 124例)。
  • 从临床记录收集青春期、生长和治疗数据,按促生长治疗使用情况绘制生长曲线。

主要发现

  • 诊断中位年龄0.1岁(IQR 0.03-1.1),末次随访中位年龄12.1岁(IQR 7.0-17.0)。
  • 46,XX最终身高中位数154.0 cm(IQR 147.3-158.2),月经初潮中位年龄13.0岁;46,XY最终身高中位数167.0 cm(IQR 160.0-170.0)。
  • 全队列63.4%处于青春期/青春期后,促生长治疗单用或联用比例41.1%。
  • GnRH类似物、醋酸环丙孕酮、芳香化酶抑制剂使用比例分别为21.8%(n=62)、8.1%(n=23)、5.3%(n=15)。
  • 最终身高与遗传靶身高差值:男孩无促生长治疗为-6.7 cm,有促生长治疗为-2.3 cm;女孩无促生长治疗为-3.7 cm,有促生长治疗为-6.6 cm。

临床怎么用

  • 对经典21-OHD患者应关注青春期生长模式,尤其女孩青春期提前、节奏慢、持续时间长。
  • 促生长治疗决策需个体化,男孩可能获益,女孩需谨慎评估。

局限性

  • 回顾性研究设计。
  • 数据来自临床记录。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD) poses significant growth challenges, including accelerated bone maturation, precocious puberty, and compromised final height (FH). Data on pubertal growth in large 21-OHD cohorts remain limited. OBJECTIVE: To assess puberty timing, duration, height gain, FH outcomes, and the effects of growth-promoting therapies (GPTs), including GnRH analog, aromatase inhibitors, and cyproterone acetate, in a large cohort with genetically confirmed classical 21-OHD. DESIGN AND SETTING: A multicenter, retrospective, longitudinal analysis of 284 patients (46,XX: 160; 46,XY: 124). METHODS: Data on puberty, growth, and treatments were collected from clinical records. Growth curves were plotted based on GPT use. RESULTS: Median age at diagnosis was 0.1 years (interquartile range [IQR]: 0.03-1.1), and at last visit, 12.1 years (IQR: 7.0-17.0). Median FH was 154.0 cm (IQR: 147.3-158.2) in 46,XX (menarche at 13.0 years) and 167.0 cm (IQR: 160.0-170.0) in 46,XY. In the total cohort, 63.4% were pubertal/postpubertal, and the ratio of GPTs used alone or in combination was 41.1%. GnRH analogs, cyproterone acetate, and aromatase inhibitors were administered in 21.8% (n = 62), 8.1% (n = 23), and 5.3% (n = 15) of the cohort, respectively. The median FH-MPH difference improved from -6.7 cm to -2.3 cm in boys without and with GPT, respectively, whereas in girls it declined from -3.7 cm to -6.6 cm. CONCLUSION: Patients with 21-OHD had diminished FH despite early diagnosis. Puberty in classical 21-OHD had an earlier onset, slower tempo, and prolonged duration, especially in girls, in which GPTs are less effective in promoting height. The management of pubertal growth needs a personalized approach in patients with classical 21-OHD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yavas Abali Z, Yildiz M, Abali S, et al. Impact of Growth-promoting Therapies on Puberty, Growth, and Final Height in Classical 21-hydroxylase Deficiency. J Clin Endocrinol Metab. 2026. PMID: 41349002. doi:10.1210/clinem/dgaf612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。